Published in Women's Health Weekly, July 13th, 2006
Study 1: Premenstrual dysphoric disorder responds to a limited serotonin reuptake inhibitor dosing strategy.
"Symptoms of premenstrual dysphoric disorder (PMDD) respond to serotonin reuptake inhibitors when treatment is limited to 14 days of the menstrual cycle. Many women have less than a week of symptoms, and shorter treatment intervals would further reduce medication exposure and costs," stated investigators at Yale University.
K.A. Yonkers and colleagues explained, "Twenty women with PMDD were randomly assigned to either paroxetine CR or placebo...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly